Geron Corp. is virtually synonymous with telomerase, but another company, Gemini Technologies Inc., is the first to report preclinical results related to the enzyme. Gemini, an 80 percent-owned subsidiary of Atlantic Pharmaceuticals Inc. (ATLC), last week presented preclinical results with a 2-5A antisense compound that inhibited the growth of glioblastoma cells transplanted into mice (see B10). The compound targets the RNA component of telomerase.

ATLC President and CEO J.D. Lindjord